IL2 and hereditary clear cell renal cell carcinoma: For patients with lymph nodes and/or other distant organ metastases, cytokine therapy including IL-2 and IFN-α and vascular endothelial growth factor targeted therapy (such as sunitinib, sorafenib and monoclonal anti-VEGF antibodies) are required.[13,14] Choueiri et al[14] divided 15 patients with adult metastatic Xp 11.2 translocation renal cell carcinoma into 3 groups.